Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The object of this study was to compare the relative bioavailability (rate and extent of
absorption) of 100/25 mg Losartan potassium/Hydrochlorothiazide Tablets manufactured by Teva
Pharmaceutical Industries Ltd. and distributed by Teva Pharmaceuticals USA with that of
Hyzaar® 100/25 mg Tablets distributed by Merck & Co., Inc. following a single oral dose (1 x
100/25 mg tablet) in healthy adult subjects administered under fasting conditions.